"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...

Ipsen again raised its targets for 2024, now targeting an operating margin of over 31% of sales. GSK announced a single dose of Arexvy elicited robust immune response with acceptable safety profile in ...

GSK’s Arexvy—which became the industry’s first FDA-approved RSV shot in May 2023—was greenlit for use in adults aged 50 to 59 in June 2024. On Thursday, GSK unveiled Phase IIIb data showing that a ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy, may be ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a ...

New data for Arexvy, GSK's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease · Single dose of vaccine elicited robust ...